J G Peter1, T J Cashmore, R Meldau, G Theron, R van Zyl-Smit, K Dheda. 1. Lung Infection and Immunity Unit, Division of Pulmonology, University of Cape Town Lung Institute and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
OBJECTIVE: To examine whether a lipoarabinomannan (LAM) enzyme-linked immunosorbent assay (ELISA) that offers diagnostic utility using urine in patients with tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection can be used in induced sputum to diagnose sputum-scarce patients with suspected TB. DESIGN: LAM was measured in induced sputum samples obtained from 61 consecutively recruited sputum-scarce TB suspects in a tertiary hospital respiratory clinic in South Africa. Liquid culture positivity for Mycobacterium tuberculosis was used as the reference standard. Receiver operating characteristic analysis was used to assess alternative LAM concentration cut-offs. RESULTS: A total of 87% (53/61) of study patients had a valid M. tuberculosis culture result; 49% (23/53) were HIV-infected and 17% (9/53) were culture-positive for M. tuberculosis. Induced sputum smear microscopy and LAM ELISA had an overall sensitivity of 56% (95%CI 27-81); however, the specificity of LAM ELISA was 48% (95%CI 34-62), while the positive and negative predictive values were respectively 18% (95%CI 8-36) and 84% (95%CI 65-94). An optimal rule-in cut-off selected by receiver operating characteristic (LAM concentration >5.73 ng/ml) increased test specificity to 98% and reduced sensitivity to 22%. Normalisation of the assay for sample total protein or cell count did not improve diagnostic accuracy. CONCLUSIONS: In this proof-of-concept study, the ELISA was not clinically useful for TB diagnosis using induced sputum.
OBJECTIVE: To examine whether a lipoarabinomannan (LAM) enzyme-linked immunosorbent assay (ELISA) that offers diagnostic utility using urine in patients with tuberculosis (TB) and humanimmunodeficiency virus (HIV) co-infection can be used in induced sputum to diagnose sputum-scarce patients with suspected TB. DESIGN:LAM was measured in induced sputum samples obtained from 61 consecutively recruited sputum-scarce TB suspects in a tertiary hospital respiratory clinic in South Africa. Liquid culture positivity for Mycobacterium tuberculosis was used as the reference standard. Receiver operating characteristic analysis was used to assess alternative LAM concentration cut-offs. RESULTS: A total of 87% (53/61) of study patients had a valid M. tuberculosis culture result; 49% (23/53) were HIV-infected and 17% (9/53) were culture-positive for M. tuberculosis. Induced sputum smear microscopy and LAM ELISA had an overall sensitivity of 56% (95%CI 27-81); however, the specificity of LAM ELISA was 48% (95%CI 34-62), while the positive and negative predictive values were respectively 18% (95%CI 8-36) and 84% (95%CI 65-94). An optimal rule-in cut-off selected by receiver operating characteristic (LAM concentration >5.73 ng/ml) increased test specificity to 98% and reduced sensitivity to 22%. Normalisation of the assay for sample total protein or cell count did not improve diagnostic accuracy. CONCLUSIONS: In this proof-of-concept study, the ELISA was not clinically useful for TB diagnosis using induced sputum.
Authors: Grant Theron; Jonny Peter; Richard van Zyl-Smit; Hridesh Mishra; Elizabeth Streicher; Samuel Murray; Rodney Dawson; Andrew Whitelaw; Michael Hoelscher; Surendra Sharma; Madhukar Pai; Robin Warren; Keertan Dheda Journal: Am J Respir Crit Care Med Date: 2011-04-14 Impact factor: 21.405
Authors: Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins Journal: N Engl J Med Date: 2010-09-01 Impact factor: 91.245
Authors: Keertan Dheda; Virginia Davids; Laura Lenders; Teri Roberts; Richard Meldau; Daphne Ling; Laurence Brunet; Richard van Zyl Smit; Jonathan Peter; Clare Green; Motasim Badri; Leonardo Sechi; Surendra Sharma; Michael Hoelscher; Rodney Dawson; Andrew Whitelaw; Jonathan Blackburn; Madhukar Pai; Alimuddin Zumla Journal: PLoS One Date: 2010-03-24 Impact factor: 3.240
Authors: Keertan Dheda; Richard N Van-Zyl Smit; Leonardo A Sechi; Motasim Badri; Richard Meldau; Gregory Symons; Hoosein Khalfey; Igshaan Carr; Alice Maredza; Rodney Dawson; Helen Wainright; Andrew Whitelaw; Eric D Bateman; Alimuddin Zumla Journal: PLoS One Date: 2009-03-11 Impact factor: 3.240
Authors: H D Geldenhuys; A Whitelaw; M D Tameris; D Van As; K K A Luabeya; H Mahomed; G Hussey; W A Hanekom; M Hatherill Journal: Eur J Clin Microbiol Infect Dis Date: 2014-07-15 Impact factor: 3.267
Authors: Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah Journal: Cochrane Database Syst Rev Date: 2019-10-21
Authors: Shaheen Pandie; Jonathan G Peter; Zita S Kerbelker; Richard Meldau; Grant Theron; Ureshnie Govender; Mpiko Ntsekhe; Keertan Dheda; Bongani M Mayosi Journal: Sci Rep Date: 2016-09-16 Impact factor: 4.379
Authors: Helena Huerga; Sekai Chenai Mathabire Rucker; Loide Cossa; Mathieu Bastard; Isabel Amoros; Ivan Manhiça; Kuzani Mbendera; Alex Telnov; Elisabeth Szumilin; Elisabeth Sanchez-Padilla; Lucas Molfino Journal: PLoS Med Date: 2019-04-30 Impact factor: 11.069
Authors: Prithwiraj De; Anita G Amin; Eloise Valli; Mark D Perkins; Michael McNeil; Delphi Chatterjee Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240